Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and Exposition

LA JOLLA, Calif.–(BUSINESS WIRE)—- $EQ–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that two abstracts were accepted for presentation at the 63rd annual meeting of the American Society of Hematology to be held both in person and virtually, December 11 – 14, 2021. Title: Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is
Click here to view original post